drugset / Trial / NCT04308785
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage small cell lung cancer who have not progressed during/after chemoradiotherapy.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |